Planta Med 2019; 85(03): 231-238
DOI: 10.1055/a-0753-0400
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Icariin Improves Functional Behavior in a Mouse Model of Traumatic Brain Injury and Promotes Synaptic Plasticity Markers

Hyejin Joo
1   Department of Science in Korean medicine, Graduate School, Kyung Hee University, Seoul, Korea
2   Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Korea
,
Jinhyun Bae
2   Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Korea
,
Jun-Seon Lee
2   Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Korea
,
Yumi Bang
2   Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Korea
,
Beom-Joon Lee
3   Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Korea
,
Jae-Woo Park
3   Department of Internal Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Korea
,
Kyungjin Lee
2   Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Korea
,
Jae-Heung Cho
4   Department of Korean Rehabilitation Medicine, Kyung Hee University, Seoul, Korea
,
Youngmin Bu
2   Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Korea
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 01. Juni 2018
revised 21. September 2018

accepted 26. September 2018

Publikationsdatum:
09. Oktober 2018 (online)

Zoom Image

Abstract

Epimedii Herba (EH) has been used in traditional Asian medicine to treat hemiplegia following stroke. Icariin, its major active component, is used as a quality-control marker and for its various pharmacological effects. We hypothesized that icariin would show protective effects following traumatic brain injury (TBI). The TBI mouse model was induced using a controlled cortical impact method. Body weight, brain damage, motor function, and cognitive function were evaluated. Synaptogenesis markers were analyzed to investigate potential mechanisms of action. The animals were divided into six groups: sham, control, minocycline-treated group, and icariin-treated (3, 10, and 30 mg/kg, p. o.) groups. The icariin 30 mg/kg-treated group regained body weight at 7 and 8 d post TBI. Icariin 30 mg/kg- and 10 mg/kg-treated groups showed enhanced sensory-motor function at 8 d post TBI in rotarod and balance beam tests. Icariin-treated groups showed increased recognition index in the novel object recognition test at all doses and increased spontaneous alternation in the Y-maze test at 30 mg/kg. Icariin upregulated brain-derived neurotrophic factor, synaptophysin and postsynaptic density protein 95 expressions. However, no protective effects against brain damage or neuronal death were observed. The current results provide a basis for using icariin following TBI and suggest that it could be a candidate for the development of therapeutic agents for functional recovery after TBI.